Clinical trials: Digestive Neoplasms
Pancreatic Cancer, Ductal Adrenocarcinoma
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
The purpose of this study is to evaluate the safety and tolerability of selected dose 1.2mg/kg BID dosage administered subcutaneously (SC) administered PCI-27483 to metastatic or locally advanced pancreatic cancer patients…
- Conditions
- Pancreatic Cancer, Ductal Adrenocarcinoma, Exocrine Pancreatic Cancer
- Trial name
- NCT01020006
- Testing
- PCI-27483, Gemcitabine
- Where
- 17 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pharmacyclics LLC.
Biliary Tract Cancer
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with…
- Trial name
- FOENIX-BTC (NCT07710885)
- Testing
- Futibatinib, Zimberelimab, Durvalumab
- Where
- 21 sites in Australia, Japan and 2 more
- Volunteers
- 784 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma, Prostate Cancer
LTFU for All Cell and Gene Therapy Studies
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
- Trial name
- LOCUS (NCT06194461)
- Testing
- AZD5851, AZD0754
- Where
- 25 sites in United States, Australia and 2 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Bladder Cancer, Breast Cancer
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Picoplatin is a new platinum-based chemotherapy drug that has been studied in a variety of cancers. Phase 1 and 2 studies have demonstrated that picoplatin may be effective in patients whose cancer returns or does not improve…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastrointestinal Neoplasm
- Trial name
- NCT00465725
- Testing
- Picoplatin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Poniard Pharmaceuticals
Cancer Colorectal
ctDNA Methylation Application in Postoperative Relapse and Adjuvant Chemotherapy Efficacy Evaluation
In this study, the investigators aimed to apply their previously developed multi-locus blood-based assay targeting circulating tumor DNA methylation to monitor postoperative relapse and evaluate adjuvant chemotherapy efficacy in…
- Trial name
- NCT05536089
- Testing
- a multi-locus blood-based assay
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Singlera Genomics Inc.
Tumor
A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types
- Trial name
- CheckMate 76U (NCT04311710)
- Testing
- ipilimumab, nivolumab, ENHANZE (rHuPH20)
- Where
- 6 sites in United States, Italy and 1 more
- Volunteers
- 21 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
The purpose of this study is to determine whether TAC-101 as a second line therapy for participants who received Sorafenib as first line therapy is effective in slowing tumor activity in patients with advanced hepatocellular…
- Trial name
- NCT00687596
- Testing
- TAC-101
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Taiho Oncology, Inc.
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07284186
- Testing
- PLX-61639
- Where
- 10 sites in United States
- Volunteers
- 155 people
- Sponsor
- Plexium, Inc.
Biliary Tract Cancer
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
To evaluate the efficacy and safety TQB2102 for injection in the treatment of patients with Her2-positive biliary tract cancer.
- Trial name
- NCT06431490
- Testing
- TQB2102 for injection
- Where
- 43 sites in China
- Volunteers
- 102 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Colorectal Cancer
A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment
The purpose of this study is to investigate the safety and possible efficacy of the use of pentamidine in the treatment of colon cancer metastasis in subjects receiving standard therapy.
- Trial name
- NCT00809796
- Testing
- pentamidine
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Oncozyme Pharma Inc.
Pancreatic Cancer, Bile Duct Cancer
A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers
This registry will collect data from patients routinely undergoing an ERCP and Cellvizio endomicroscopy procedure (and optionally an additional cholangiopancreatoscopy procedure) due to suspected pancreatic or bile duct cancer.
- Trial name
- NCT00779688
- Testing
- Probe-based confocal laser endomicroscopy
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 130 people
- Sponsor
- Mauna Kea Technologies
Locally Advanced Tumor, Metastatic Solid Tissue Tumors
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
The study comprises a Phase I component during which the optimal dose of DCVax-Direct for the treatment of solid tissue tumors will be identified, followed by a Phase II component to determine if the injection of DCVax-Direct…
- Conditions
- Locally Advanced Tumor, Metastatic Solid Tissue Tumors, Liver Cancer, Colorectal Cancer
- Trial name
- NCT01882946
- Testing
- DCVax-Direct
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Northwest Biotherapeutics
Barrett's Esophagus
Barrett's Esophagus - 315 - 3 Way Cross Over
This study evaluates PGE2 production, COX-2 enzyme activity and PCNA expression in Barrett's metaplastic tissue. All patients will have a baseline endoscopy with multiple biopsies.
- Trial name
- NCT00637988
- Testing
- Esomeprazole, Aspirin, Rofecoxib
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Gastrointestinal Stromal Tumors
Study for Patients Previously Treated in Avapritinib Clinical Trials
This is an open-label extension study to provide long term safety data for GIST patients who are deriving clinical benefit from avapritinib upon the completion of avapritinib clinical trials.
- Trial name
- NCT04825574
- Testing
- Avapritinib
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Blueprint Medicines Corporation
Non Small Cell Lung Cancer, Pancreatic Cancer
Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.
The aim of the study is to assess the feasibility of genomic and epigenetic analysis of rectal mucus to detect non-colorectal cancers of the aero- digestive tract using samples collected by the OriCol™ Sampling Device.
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- ORI-EGI-03 (NCT05102110)
- Testing
- Oricol Test
- Where
- United Kingdom
- Volunteers
- 450 people
- Sponsor
- Origin Sciences
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.
- Trial name
- NCT00343460
- Testing
- APF530, dexamethasone, Palonosetron Hydrochloride
- Where
- 52 sites in United States
- Volunteers
- 1,428 people
- Sponsor
- Heron Therapeutics
Pancreatic Cancer, Non-small Cell Lung Cancer
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
The primary objective of the study is to determine the maximum tolerated dose of andecaliximab monotherapy and to evaluate the safety and tolerability of andecaliximab (formerly GS-5745) alone and in combination with…
- Conditions
- Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer
- Trial name
- NCT01803282
- Testing
- Andecaliximab, Gemcitabine, Nab-paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 236 people
- Sponsor
- Gilead Sciences
Colorectal Cancer
Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer
This study will evaluate the efficacy, safety and pharmacokinetics of capecitabine (2000 mg/m2/day by mouth [po], day 1 pm-day 15 am every 3 weeks [q3w]), oxaliplatin (130 mg/m2 intravenously [iv], day 1 q3w) and bevacizumab (7.5…
- Trial name
- NCT00345761
- Testing
- Bevacizumab, Oxaliplatin, Capecitabine
- Where
- 4 sites in Japan
- Volunteers
- 64 people
- Sponsor
- Chugai Pharmaceutical
Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced…
- Trial name
- PHOCUS (NCT02562755)
- Testing
- Pexastimogene Devacirepvec (Pexa Vec), Sorafenib
- Where
- 142 sites in United States, Australia and 14 more
- Volunteers
- 459 people
- Sponsor
- SillaJen, Inc.
Neoplasm, Gastric
Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer
This is a multicenter, single arm, open-label Phase 1/2 study of pemetrexed plus cisplatin for patients with unresectable, advanced gastric cancer who had no prior palliative chemotherapy.
- Trial name
- NCT00320515
- Testing
- pemetrexed, cisplatin
- Where
- 8 sites in Argentina, Mexico and 2 more
- Volunteers
- 89 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.